Clinical Trial Update: Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nivolumab and ibrutinib in relapsed/refractory or high-risk untreated chronic lymphocytic leukemia, small lymphocytic lymphoma, or Rich…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Richter Transformation
• Small Lymphocytic Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)
• nivolumab (nivolumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Loss of Chromosome 17p, Recurrent Chronic Lymphocytic Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2024-03-20